



PO Box 56099
Madison, WI 53705-9399

Business offices in
Saint Louis, MO & Madison, WI

phone: 866-514-4194

TTY: 711

wellfirstbenefits.com

August 30, 2021

Dear WellFirst Health Provider:

Thank you for your continued dedication and commitment to providing high-quality care to our members during the public health emergency.

This notification contains information regarding:

- U.S. Food and Drug Administration's (FDA's) full approval of the Pfizer-BioNTech COVID-19 vaccine for individuals 16 years of age and older.
- FDA emergency use authorizations (EUAs) for a third dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine to immunocompromised individuals.

Information in this notification applies to the following WellFirst Health products: ACA Individual, Medicare Advantage, and SSM Health Employee Health Plan Administrative Services Only (ASO) in Illinois, Missouri, and Oklahoma.

FDA Full Approval of Pfizer-BioNTech COVID-19 Vaccine for Those 16 Years and Older

On August 23, 2021, the [FDA fully approved the Pfizer-BioNTech COVID-19 vaccine for individuals 16 years of age and older](#). This replaces the EUA approval for this age group. The vaccine also continues to be available under EUA for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals, as detailed in the following section.

With full FDA approval, the vaccine will now be marketed as Comirnaty.

Additional COVID-19 Vaccine Dose for Immunocompromised Individuals

On August 12, 2021, the [FDA amended the EUAs for both the Pfizer-BioNTech and the Moderna COVID-19 vaccines to allow a third dose to immunocompromised individuals](#). Immunocompromised individuals are solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

The following CPT codes have been established for a third dose vaccine administration:

- Pfizer-BioNTech; 0003A - Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose
- Moderna; 0013A - Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose

The amended EUAs allow for an additional dose to be administered at least 28 days following the two-dose regimen of the same vaccine to immunocompromised individuals ages 12 years or older for Pfizer-BioNTech or 18 years or older for Moderna.

Member cost share is waived for a third dose of a vaccine when administered consistent with the amended EUA. Providers should submit claims for vaccine administration to WellFirst Health, except for [Medicare Advantage claims which must be submitted directly to Centers for Medicare and Medicaid Services](#).


Additional Health Plan Information

For additional health plan information and previous provider communications, refer to our [COVID-19 provider information web page](#) link located at the top of all [wellfirstbenefits.com](#) web pages. Providers are encouraged to check our website regularly for new and updated information.

Please contact a WellFirst Health Provider Network Consultant at 314-994-6262 or ProviderRelations@wellfirstbenefits.com.

Thank you again for your commitment to our members.

Sincerely,



Loretta A. Lorenzen
Vice President- Network Management & Contracting